Experimental cancer drug trial halted early

NCT ID NCT05983133

Terminated Disease control Sponsor: Seagen, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head and neck, and pancreatic cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm head and neck squamous cell carcinoma non-small cell lung carcinoma pancreatic ductal adenocarcinoma rectal neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL NEOPLASMS PANCREATIC DUCTAL ADENOCARCINOMA SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Contacts and locations

Locations

Atrium Health Wake forest Baptist

Winston-Salem, North Carolina, 27157, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Huntsman Cancer Hospital, University of Utah

Salt Lake City, Utah, 84112, United States
Huntsman Cancer Institute, University Of Utah

Salt Lake City, Utah, 84112, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States
MD Anderson Cancer Center - University of Texas

Houston, Texas, 77030, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moffitt Cancer Center McKinley Hospital

Tampa, Florida, 33612, United States
Providence Cancer Institute Franz Clinic

Portland, Oregon, 97213, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Ronald Reagan UCLA Medical Center

Los Angeles, California, 90095, United States
Santa Monica UCLA Medical Center & Orthopaedic Hospital

Santa Monica, California, 90404, United States
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UCLA Hematology/Oncology

Los Angeles, California, 90095, United States
UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, 90404, United States
University College London Hospital, NIHR UCLH Clinical Research Facility

London, W1T 7HA, United Kingdom
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Utah

Salt Lake City, Utah, 84112, United States
Wake Forest Baptist Medical Center / Wake Forest University

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.